

1 **Title:** Assessment of Regional Body Composition, Physical Function and Sarcopenia  
2 among Peruvian women aging with HIV

3 **Authors:**

4 Diego M. Cabrera<sup>1,2,3</sup>, Mijahil P. Cornejo<sup>4</sup>, Yvett Pinedo<sup>5</sup>, Patricia J. Garcia,<sup>3</sup> and Evelyn  
5 Hsieh<sup>1</sup>

6 **Authors affiliations:**

- 7 1. Section of Rheumatology, Allergy and Immunology, Yale School of Medicine,  
8 New Haven, CT, USA  
9 2. Department of Epidemiology of Microbial Diseases, Yale School of Public Health,  
10 New Haven, CT, USA  
11 3. Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana  
12 Cayetano Heredia, Lima, Peru  
13 4. Department of Rheumatology, Hospital Nacional Arzobispo Loayza, Lima, Peru  
14 5. Department of Infectious Diseases, Hospital Nacional Arzobispo Loayza, Lima,  
15 Peru

16 **Correspondence Author:** Evelyn Hsieh, MD, PhD.; Section of Rheumatology, Allergy  
17 and Immunology, Yale School of Medicine, 300 Cedar Street TAC S-525, PO Box  
18 208031, New Haven, CT 06520-8031; [evelyn.hsieh@yale.edu](mailto:evelyn.hsieh@yale.edu)

19 **ABSTRACT**

20 **Background:** Management of chronic conditions and optimization of overall health has  
21 become a primary global health concern in the care of people living with HIV, particularly  
22 in lower-and-middle income countries where infrastructure for chronic disease  
23 management may be fragmented. Alterations in body composition (BC) can reflect  
24 important changes in musculoskeletal health, particularly among populations at risk for  
25 developing fat and muscle redistribution syndromes, such as HIV-infected women. We  
26 aimed to explore this issue among Peruvian women aging with HIV.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Methods:** Cross-sectional study among HIV-infected and uninfected Peruvian women  
28 aged  $\geq 40$ . Dual X-ray absorptiometry was used to measure trunk and limb lean mass  
29 (LM) and fat mass (FM). Physical performance was assessed with the Short Physical  
30 Performance Battery (SPPB) and physical strength with a dynamometer. Sarcopenia  
31 was assessed based upon EWGSOP criteria. We used linear regression to model  
32 associations between BC, sarcopenia and physical scores.

33 **Results:** 104 HIV-infected and 212 uninfected women were enrolled with a mean age of  
34  $55.1 \pm 8.8$  years. Among the HIV-infected group, years since diagnosis was  $11.8 \pm 6$  and  
35 all were on antiretroviral treatment. Mean SPPB score was 9.9 vs 10.8 ( $p < 0.001$ )  
36 between both groups. Sarcopenia spectrum was found in 25.9% of HIV-infected and  
37 23.1% of uninfected women. In multivariate regression analysis, trunk FM and older age  
38 were negatively correlated with physical performance among HIV-infected women. An  
39 increased percentage of severe sarcopenia was found among the HIV-infected, although  
40 our study was not specifically powered for this comparison.

41 **Conclusions:** HIV-infected women had significantly lower SPPB scores compared to  
42 women without HIV, and trunk FM and upper limb LM were independent predictors for  
43 the tests described. Prospective studies are needed in Latin America & the Caribbean to  
44 identify individuals at high risk for declines in physical function, and inform prevention  
45 guidelines.

46 **Key words:** Body composition, SPPB, Sarcopenia, HIV, women, Peru

47

## 48 **INTRODUCTION**

49 With continued improvements in survival rates, management of chronic conditions and  
50 optimization of overall health has become a primary global health concern in the care of  
51 people living with HIV (PLWH)[1], particularly in lower-and-middle income countries  
52 where infrastructure for chronic disease management may be fragmented. Studies have  
53 shown that onset of aging-related comorbidities appears to occur in PLWH approximately

54 a decade earlier compared with the general population[2]. The burden of aging in PLWH  
55 represents a relatively new and complex condition globally, that may lead to a decline in  
56 physical function and vulnerability to injury or developing other pathologies[3]. In Latin  
57 America & the Caribbean (LAC) few studies have focused on the impact of aging-related  
58 comorbidities among middle-aged and older PLWH. Therefore an important research  
59 agenda remains to characterize the epidemiology and outcomes of these co-morbidities  
60 taking into account sociocultural and health systems related factors unique to this region  
61 [4].

62 The musculoskeletal (MSK) system is significantly affected by HIV and its treatment.  
63 Compared with the general population, PLWH present with accelerated bone mineral  
64 density loss, increased incidence of low bone mass and heterogeneous disorders of  
65 body composition, often associated with metabolic consequences[5,6]. Alterations in  
66 body composition, such as sarcopenia and fat redistribution, can reflect important  
67 changes in bone and MSK health[7]. Consequently, sarcopenia has been described as  
68 an age-related decline in muscle mass that impairs physical function, with well-  
69 established associations with morbidity and mortality[8].

70 As PLWH age with these comorbidities, the heterogeneity of older individuals with HIV  
71 highlights the relevance of identifying those who are at greatest risk of premature  
72 aging[9]. The Short Physical Performance Battery (SPPB) is an objective physical  
73 functioning assessment that measures physical performance in older populations and  
74 has been extensively used in research settings to identify patients at risk of adverse  
75 events[10,11]. Physical function measures have multiple applications among aging  
76 adults including identification of those at increased likelihood of poor outcomes, which  
77 may allow clinicians to identify high-risk older individuals and prioritize them for  
78 preventive interventions[12].

79 Although more than half of PLWH worldwide currently are women, there is limited data  
80 about the specific characteristics of women aging with HIV[13]. Furthermore, no studies  
81 have focused on the relationship between body composition changes, sarcopenia and

82 physical function among women with HIV in LAC. We aimed to explore the scope of this  
83 issue among Peruvian women aging with HIV using Dual X-ray absorptiometry (DXA)-  
84 based body composition measures and the well-established SPPB.

## 85 **METHODS**

### 86 ***Study design and participants***

87 We conducted a hospital-based cross-sectional study. Between October 2019 and  
88 March 2020, participants were invited to participate at a large HIV-clinic from a public  
89 hospital in Lima, Peru. We enrolled HIV-positive women aged  $\geq 40$  years who presented  
90 for routine HIV-care visits during the study period, and concurrently recruited a control  
91 group of HIV-uninfected women aged  $\geq 40$  years. We used two strategies to recruit  
92 women in the control group, including inviting community-dwelling women from  
93 surrounding neighborhoods and as well as advertising the study among hospital staff  
94 (administrators, nurses and technicians). Exclusion criteria included pregnancy  
95 (assessed with urine pregnancy test at recruitment), previous diagnosis of or treatment  
96 for osteoporosis, and insufficient literacy to complete the questionnaire. Written informed  
97 consent was obtained in accordance with the procedures approved by the ethics  
98 committees from Yale School of Medicine, Universidad Peruana Cayetano Heredia and  
99 Hospital Nacional Arzobispo Loayza.

### 100 ***Data collection and measures***

101 Participants completed a self-administered questionnaire including socio-demographic  
102 and clinical data. Questionnaires were piloted before enrollment among 10 patients and  
103 10 clinic staff to assure ease of use and clarity. HIV-related characteristics such as CD4<sup>+</sup>  
104 T-cell count, viral load and antiretroviral therapy (ART) were obtained from medical  
105 records. HIV viral load suppression was defined as  $< 50$  copies/ml. Anthropometric  
106 measures were obtained using the same standardized stadiometer and weight scale for  
107 all participants. Waist and hip circumferences were measured to the closest 0.1 cm using  
108 a non-elastic tape measure.

## 109 ***Body composition measurements***

110 DXA was performed using a Hologic Discovery – WI 2009 series 84453 machine  
111 (Hologic Inc, Waltham, MA, USA). Scans of the whole body were performed using the  
112 automatic scan mode with participants wearing light clothing according to standard  
113 procedures. Body composition measures included trunk and limb lean mass (LM), fat  
114 mass (FM) and bone mineral content (BMC), all measured in grams. The fat mass index  
115 (FMI), skeletal muscle mass index (SMI) and appendicular skeletal muscle mass index  
116 (ASMI) were calculated as total body FM, total body LM and limb LM divided by the  
117 square of height ( $\text{kg}/\text{m}^2$ ), respectively[14]. Daily calibration and long-term DXA stability  
118 monitoring were performed according to standard protocols using manufacturer  
119 phantoms.

## 120 ***Tests of physical function and strength***

121 The SPPB was selected as an evidence-based, quick-to-perform physical function  
122 assessment. This tool has been used for more than 20 years to assess performance and  
123 functional status in aging populations[11]. The SPPB includes timed measures of  
124 standing balance in 3 positions (side-by-side, semi-tandem, and tandem), 4-meter gait  
125 speed, and time required to stand up and sit down 5 times. The test was performed  
126 according to the National Institute on Aging protocol[15]. Each measure was designated  
127 a score from 0 to 4, with 0 indicating inability to complete the test. Composite measures  
128 yielded a total score from 0 to 12, where a score  $\leq 8$  was used to indicate disability/low  
129 physical function[12,16].

130 Physical strength was assessed with hand grip strength using a JAMAR hydraulic hand  
131 dynamometer (Patterson Medical, IL, USA), which is the most widely used dynamometer  
132 in the research setting, and has been validated in several different patient populations  
133 and countries for measuring grip strength[17,18]. Force was measured in kilograms  
134 according to standardized procedures. Participants were asked to sit with their shoulder  
135 adducted and neutrally rotated, elbow flexed at  $90^\circ$  and with the forearm in a neutral  
136 position maximally squeeze the handle of the dynamometer with their dominant hand for

137 three seconds. We set the dynamometer on the second handle position and performed  
138 the test three successive times, the average of the three trials was recorded.

### 139 ***Sarcopenia Spectrum***

140 Sarcopenia was defined and staged according to the European Sarcopenia Working  
141 Group (EWGSOP) guidelines[19], which recommends the presence of low muscle mass  
142 ( $ASMI \leq 5.67 \text{ kg/m}^2$ ) and low muscle function (strength [grip strength  $\leq 20\text{kg}$ ] or  
143 performance [SPPB  $\leq 8$ ]) for diagnosis of this syndrome[20–22]. The "presarcopenia"  
144 stage was defined as low muscle mass without impact on muscle strength or  
145 performance. The "sarcopenia" stage was defined as low muscle mass, plus low muscle  
146 strength or physical performance and "severe sarcopenia" was defined when all three  
147 criteria of the definition were met.

### 148 ***Statistical analysis***

149 We described the sample characteristics and outcomes using standard frequency  
150 analysis, means, standard deviations, and proportions for all variables, as appropriate.  
151 Differences between HIV-infected and uninfected women were examined using  
152 independent t-test,  $\chi^2$ , and Fisher exact test, as appropriate.

153 Unadjusted and adjusted linear regression models were adopted separately for the HIV-  
154 infected and uninfected women to further analyze associations of independent variables  
155 (sociodemographic, clinical characteristics and body composition measurements) and  
156 physical function (SPPB and grip strength). Two multivariable models were constructed  
157 for the independent variables and SPPB, and grip strength separately. We first assessed  
158 for possible multicollinearity of the independent variables. Variables with a high  
159 correlation coefficient ( $r > 0.40$ ) were deemed collinear and excluded for the models. We  
160 fit the multivariate models using backward regression[23], starting with all the variables  
161 that showed a hypothesized relationship ( $p < 0.10$ ) in the bivariate model. We then  
162 removed non-significant ( $p > 0.05$ ) variables one at a time beginning with the least  
163 significant (largest p-value), in order to achieve the most parsimonious model.

164 Association between the sarcopenia spectrum (presarcopenia, sarcopenia and severe  
 165 sarcopenia) and both sociodemographic and clinical related factors were explored with  
 166 logistic regression analysis, applying the same steps mentioned above. Results were  
 167 reported as unadjusted and adjusted standardized beta coefficients or odds ratio (OR)  
 168 with 95% confidence intervals, as appropriate. All statistical analyses were performed  
 169 using STATA version 16 (StataCorp, College Station, Texas, USA).

## 170 **RESULTS**

### 171 ***Sociodemographic and clinical characteristics***

172 A total of 316 women were recruited in this study, including 104 HIV-infected and 212  
 173 uninfected women. The mean age of uninfected women was slightly older than women  
 174 with HIV (56.4±8.8 vs 52.4±8.2 years, p<001). Women with HIV had a lower mean body  
 175 mass index (BMI) (24.4 kg/m<sup>2</sup> vs 27.6, p=0.05) compared to uninfected women, and a  
 176 lower percentage of them had high school education or above (65.4% vs 85%, p<0.001)  
 177 compared to the control group. Postmenopausal women represented 81% of the entire  
 178 sample (Table 1).

179 **Table 1. Sociodemographic and Clinical Characteristics by HIV status**

	HIV-infected N=104	Uninfected N=212
<b>Sociodemographic characteristics</b>		
Age, mean (SD)	<b>52.38 (8.15)</b>	<b>56.37 (8.8)¥</b>
Marital status, n(%)		
Single/divorced/separated/widowed, n(%)	<b>74 (71.15)</b>	<b>95 (44.81)¥</b>
Married/cohabitant, n(%)	30 (28.85)	117 (55.19)
Ethnicity		
Caucasian, n(%)	3 (2.88)	24 (11.32)
Mestizo, n(%)	<b>97 (93.27)</b>	<b>185 (87.26)*</b>
Black, n(%)	4 (3.85)	3 (1.42)
Education level		
High school education or above, n(%)	<b>68 (65.38)</b>	<b>181 (85.38)¥</b>
<b>Clinical characteristics</b>		
Body mass index (kg/m <sup>2</sup> ), mean (SD)	<b>26.44 (5.1)</b>	<b>27.63 (4.12)*</b>
Smoking ever, n (%)	28 (26.92)	39 (18.4)
Current alcohol use, n(%)	25 (24.04)	60 (28.3)
Current use of bone nutritional supplements, n(%)	5 (4.81)	11 (5.19)
Rheumatoid arthritis diagnosis, n(%)	-	6 (2.83)

Postmenopausal status, n(%)	80 (76.92)	177 (83.49)
<b>HIV-related clinical data</b>		
Years since HIV diagnosis mean (SD)	11.81 (6.16)	-
Nadir CD4+ cell count mean (SD)	264.32 (174.34)	-
Nadir HIV viral load mean (SD)	128200.2 (275567.1)	-
Current CD4+ cell count mean (SD)	593.23 (297.5)	-
Current HIV viral load mean (SD)	30887.17 (222988.9)	-
AIDS diagnosis n(%)	8 (7.69)	-
Duration ART exposure (years) mean (SD)	9.86 (5.27)	-
PI exposure n(%)	32 (30.77)	-
NRTI exposure n(%)	103 (99.04)	-
<b>Body composition measurements</b>		
Upper limb		
FM (kg), mean (SD)	<b>3.34 (1.76)</b>	<b>3.79 (1.62)*</b>
LM (kg), mean (SD)	3.5 (0.78)	3.53 (0.7)
BMC (kg), mean (SD)	<b>0.21 (0.04)</b>	<b>0.22 (0.04)*</b>
Lower limb		
FM (kg), mean (SD)	<b>6.53 (2.43)</b>	<b>8.14 (2.17)¥</b>
LM (kg), mean (SD)	11.47 (2.18)	11.47 (1.72)
BMC (kg), mean (SD)	<b>0.56 (0.12)</b>	<b>0.59 (0.11)*</b>
Trunk FM (kg), mean (SD)	<b>11.54 (3.6)</b>	<b>12.71 (3.22)‡</b>
Total body		
FM (kg), mean (SD)	<b>22.66 (7.24)</b>	<b>25.86 (6.51)¥</b>
LM (kg), mean (SD)	37.33 (6.33)	37.65 (4.88)
BMC (kg), mean (SD)	1.74 (0.32)	1.79 (0.28)
ASMI	6.31 (1.04)	6.3 (0.88)
FMI	<b>9.59 (3.02)</b>	<b>10.88 (2.67)¥</b>
SMI	15.76 (2.42)	15.84 (1.89)

SD, standard deviation; FM, fat mass; LM, lean mass; BMC, bone mineral content; ASMI, appendicular skeletal muscle index; FMI, fat mass index; SMI, skeletal mass index; PI, protein inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; CD4+ cell count = cell/mm<sup>3</sup>; HIV viral load = copies (ml); \*p ≤ 0.05; ‡p ≤ 0.01; ¥p ≤ 0.001

180

181 Among women with HIV, the mean time since HIV diagnosis was 11.8±6 years and all  
 182 women were currently receiving ART (mean duration of treatment=9.9±5.3 years). The  
 183 current mean CD4<sup>+</sup> T-cell count was 593.2±297.5 cells/mm<sup>3</sup> and the mean CD4<sup>+</sup> T-cell  
 184 count nadir was 264.3±174.3 cells/mm<sup>3</sup>. 78.8% had an undetectable viral load.

### 185 **Body composition, physical function and strength, and sarcopenia**

186 In terms of body composition measures, women with HIV had decreased total FM  
 187 (p<0.001) compared to uninfected women. Significant differences were found between  
 188 FMI (p<0.001), upper limb FM (p=0.02), lower limb FM (p<0.001) and trunk FM (p=0.004)  
 189 between both groups. LM was found to be lower in the upper limb and total body of HIV-

190 infected women compared to the control group, but these comparisons were not  
191 statistically different.

192 The overall SPPB score was slightly lower in HIV-infected women compared to the  
193 control group (9.9 vs 10.8,  $p < 0.001$ ). A notable difference was observed in the proportion  
194 of patients with SPPB score  $\leq 8$ , but this did not reach statistical significance (16.4% vs  
195 4.7%,  $p = 0.099$ ) (Table 2). Small but statistically significant differences were found in  
196 SPPB sub-scores between the two groups, including the balance test scores (3.7 vs 3.9,  
197  $p < 0.001$ ), gait speed test scores (3.6 vs 3.7,  $p = 0.01$ ) and chair stand test scores (2.8 vs  
198 3.1,  $p < 0.001$ ). Average repeated grip strength was similar in the two groups ( $19.9 \pm 5.9$   
199 kg vs  $19.8 \pm 5.4$  kg).

**Table 2:** Physical function and strength test and Sarcopenia stages according to HIV status

Characteristics	HIV-infected women N= 104	Uninfected women N = 212	P-value
<b>Physical function and strength tests</b>			
<b>SPPB</b>			
Overall score, mean (SD)	9.99 (1.4)	10.81 (1.12)	<b>&lt;0.001</b>
score $\leq 8$ N(%)	17 (16.35)	10 (4.72)	0.099
score $> 8$ N(%)	87 (83.65)	202 (95.28)	<b>&lt;0.001</b>
Balance test, mean (SD)	3.68 (0.51)	3.86 (0.36)	<b>&lt;0.001</b>
Gait test, mean (SD)	3.56 (0.55)	3.71 (0.48)	<b>0.01</b>
Chair stand test, mean (SD)	2.75 (0.71)	3.14 (0.77)	<b>&lt;0.001</b>
<b>Grip Strength</b>			
Score (kg), mean (SD)	19.93 (5.91)	19.78 (5.44)	0.825
<b>Stages and components of sarcopenia</b>			
<b>Presarcopenia, n (%)</b>			
ASMI (kg/m <sup>2</sup> ), mean (SD)	5.32 (0.3)	5.24 (0.4)	0.709
Grip strength (kg), mean (SD)	23.57 (1.9)	25.5 (3.2)	0.168
SPPB, mean (SD)	10.71 (0.8)	11.66 (0.7)	<b>0.009</b>
<b>Sarcopenia, n (%)</b>			
ASMI (kg/m <sup>2</sup> ), mean (SD)	5.18 (0.4)	5.21 (0.3)	0.793
Grip strength (kg), mean (SD)	15.56 (3.5)	16.46 (3.9)	0.436
SPPB, mean (SD)	10.13 (0.9)	10.89 (0.9)	<b>0.008</b>
<b>Severe sarcopenia, n (%)</b>			
ASMI (kg/m <sup>2</sup> ), mean (SD)	4 (3.8)	2 (0.9)	0.84
Grip strength (kg), mean (SD)	4.59 (0.7)	5.06 (0.1)	0.399
SPPB, mean (SD)	16.75 (2.5)	13 (4.2)	0.226
SPPB, mean (SD)	7.5 (1)	7.5 (0.7)	1

*SPPB, short physical performance battery; SD, standard deviation; ASMI, appendicular skeletal mass index*

*Presarcopenia: ASMI  $\leq 5.67$  kg/m<sup>2</sup> and Grip Strength  $>20$ kg and SPPB overall score  $>8$*

*Sarcopenia: ASMI  $\leq 5.67$  kg/m<sup>2</sup> and (Grip Strength  $\leq 20$ kg or SPPB overall score  $\leq 8$ )*

*Severe sarcopenia: ASMI  $\leq 5.67$  kg/m<sup>2</sup> and Grip Strength  $\leq 20$ kg and SPPB overall score  $\leq 8$*

200

201 In terms of the sarcopenia spectrum, 25.9% of HIV-infected and 23.1% uninfected  
202 women met criteria for either presarcopenia, sarcopenia or severe sarcopenia, but this  
203 difference did not reach statistical significance. Sarcopenia stage was the most common  
204 overall (15.4% in HIV-infected vs 16.5% uninfected women), and severe sarcopenia was  
205 higher in the HIV-infected subset (3.8% vs 0.9%), but was not statistically different.  
206 Moreover, although ASMI was higher among uninfected women compared with HIV-  
207 infected women for both sarcopenia and severe sarcopenia stages, the differences were  
208 not statically significant. **(Table 2)**

209 ***Associations between clinical characteristics, body composition, and physical***  
210 ***function assessments***

211 In terms of physical function, the multivariable analysis among uninfected women  
212 showed that higher SPPB score was independently associated with current alcohol use  
213 ( $p=0.01$ ) and higher lower limb BMC ( $p=0.03$ ), and lower SPPB score was significantly  
214 associated with older age ( $p<0.001$ ) and higher BMI ( $p<0.001$ ) (Table 3). However, in  
215 the multivariable model for HIV-infected women, only trunk FM ( $p=0.038$ ) and older age  
216 ( $p=0.002$ ) were negatively correlated with SPPB score. (Table 4)

217 Regarding physical strength, in the uninfected women multivariable model, greater grip  
218 strength was positively correlated with upper limb LM ( $p<0.001$ ), and negatively  
219 correlated with older age ( $p<0.001$ ) (Table 3). Similarly, among HIV-infected women, the  
220 multivariable model showed upper limb LM ( $p<0.001$ ) and higher CD4<sup>+</sup> T-cell count  
221 ( $p=0.012$ ) were positively correlated with grip strength, and older age ( $p=0.13$ ) and total  
222 body fat percentage ( $p<0.001$ ) were negatively correlated with this outcome. (Table 4)

223

224

225

226

227

228

229

230

**Table 3.** Unadjusted and Adjusted linear regression for SPPB and Grip Strength, Uninfected Women (N=212)

Independent variables	SPPB				Grip strength test			
	Unadjusted		Adjusted		Unadjusted		Adjusted	
	B	95% C.I.	B	95% C.I.	B	95% C.I.	B	95% C.I.
<b>Body composition measurements</b>								
Trunk FM	<b>-0.064</b>	<b>-0.117 to -0.012*</b>	-	-	0.147	-0.082 to 0.375	-	-
Trunk BMC	<b>1.892</b>	<b>0.001 to 3.784*</b>	-	-	<b>15.208</b>	<b>7.281 to 23.135¥</b>	-	-
Trunk LM	0.002	-0.064 to 0.067	-	-	<b>0.386</b>	<b>0.110 to 0.662‡</b>	-	-
Trunk %fat	<b>-0.056</b>	<b>-0.093 to -0.019‡</b>	-	-	-0.046	-0.208 to 0.116	-	-
Lower limb FM	-0.056	-0.135 to 0.023	-	-	0.274	-0.065 to 0.612	-	-
Lower limb BMC	<b>1.998</b>	<b>0.427 to 3.569*</b>	<b>1.551</b>	<b>0.165 to 2.938*</b>	<b>15.495</b>	<b>8.985 to 22.004¥</b>	-	-
Lower limb LM	0.024	-0.076 to 0.124	-	-	<b>0.818</b>	<b>0.403 to 1.234¥</b>	-	-
Lower limb %fat	-0.023	-0.056 to 0.010	-	-	-0.041	-0.183 to 0.100	-	-
Upper limb FM	<b>-0.151</b>	<b>-0.255 to -0.046‡</b>	-	-	0.026	-0.431 to 0.482	-	-
Upper limb BMC	3.730	-0.188 to 7.648	-	-	<b>41.255</b>	<b>25.254 to 57.256¥</b>	-	-
Upper limb LM	0.024	-0.076 to 0.124	-	-	<b>1.746</b>	<b>0.713 to 2.779¥</b>	<b>1.804</b>	<b>0.997 to 2.611¥</b>
Upper limb %fat	<b>-0.029</b>	<b>-0.052 to -0.005*</b>	-	-	-0.097	-0.197 to 0.003	-	-
Total body FM	<b>-0.032</b>	<b>-0.058 to -0.006*</b>	-	-	0.072	-0.041 to 0.186	-	-
Total body BMC	<b>0.831</b>	<b>0.234 to 1.427‡</b>	-	-	<b>5.776</b>	<b>3.290 to 8.263¥</b>	-	-
Total body LM	0.002	-0.033 to 0.038	-	-	<b>0.272</b>	<b>0.125 to 0.419¥</b>	-	-
Total body %fat	<b>-0.055</b>	<b>-0.094 to -0.017‡</b>	-	-	-0.072	-0.242 to 0.097	-	-
<b>Sociodemographic and clinical characteristics</b>								
Age	<b>-0.067</b>	<b>-0.084 to -0.050¥</b>	<b>-0.043</b>	<b>-0.060 to -0.026¥</b>	<b>-0.194</b>	<b>-0.273 to -0.114¥</b>	<b>-0.161</b>	<b>-0.227 to -0.094¥</b>
BMI	<b>-0.061</b>	<b>-0.102 to -0.020‡</b>	<b>-0.059</b>	<b>-0.092 to -0.026¥</b>	0.105	-0.074 to 0.284	-	-
Smoking ever	0.378	-0.063 to 0.819	-	-	0.578	-1.326 to 2.482	-	-
Current alcohol use	<b>0.488</b>	<b>0.112 to 0.864*</b>	<b>0.406</b>	<b>0.090 to 0.723*</b>	-0.064	-1.703 to 1.575	-	-
Rheumatoid arthritis diagnosis	<b>-1.767</b>	<b>-2.776 to -0.758¥</b>	-	-	-3.895	-8.316 to 0.526	-	-
Menopause status	<b>-0.750</b>	<b>-1.202 to -0.298¥</b>	-	-	<b>-3.338</b>	<b>-5.274 to -1.402¥</b>	-	-
Bone nutritional supplements, ever	-0.085	-0.861 to 0.690	-	-	-0.827	-4.154 to 2.500	-	-

SPPB, short physical performance battery; FM, fat mass; LM, lean mass; BMC, bone mineral content; BMI, body mass index; %fat, percentage of FM; \* $p \leq 0.05$ ; ‡ $p \leq 0.01$ ; ¥ $p \leq 0.001$

**Table 4.** Unadjusted and Adjusted linear regression for SPPB and Grip Strength, HIV-infected women (N=104)

Independent variables	SPPB				Grip strength test			
	Unadjusted		Adjusted		Unadjusted		Adjusted	
	B	95% C.I.	B	95% C.I.	B	95% C.I.	B	95% C.I.
<b>Body composition measurements</b>								
Trunk FM	<b>-0.075</b>	<b>-0.150 to 0.001*</b>	<b>-0.076</b>	<b>-0.148 to -0.004*</b>	0.082	-0.240 to 0.404	-	-
Trunk BMC	-1.348	-4.253 to 1.556	-	-	<b>20.482</b>	<b>8.871 to 32.093‡</b>	-	-
Trunk LM	-0.061	-0.142 to 0.021	-	-	<b>0.463</b>	<b>0.126 to 0.799‡</b>	-	-
Trunk %fat	-0.029	-0.079 to 0.021	-	-	-0.157	-0.365 to 0.051	-	-
Lower limb FM	-0.095	-0.207 to 0.017	-	-	0.012	-0.466 to 0.490	-	-
Lower limb BMC	1.038	-1.279 to 3.55	-	-	<b>19.136</b>	<b>10.087 to 28.186¥</b>	-	-
Lower limb LM	-0.028	-0.155 to 0.099	-	-	<b>0.924</b>	<b>0.422 to 1.427¥</b>	-	-
Lower limb %fat	-0.023	-0.063 to 0.018	-	-	-0.165	-0.333 to 0.004	-	-
Upper limb FM	-0.130	-0.284 to 0.025	-	-	0.325	-0.332 to 0.983	-	-
Upper limb BMC	0.667	-5.810 to 7.143	-	-	<b>50.778</b>	<b>26.409 to 75.147¥</b>	-	-
Upper limb LM	-0.032	-0.387 to 0.324	-	-	<b>2.521</b>	<b>1.107 to 3.936¥</b>	<b>2.512</b>	<b>1.061 to 3.964¥</b>
Upper limb %fat	-0.018	-0.051 to 0.015	-	-	-0.072	-0.212 to 0.069	-	-
Total body FM	-0.037	-0.074 to 0.001	-	-	0.046	-0.114 to 0.207	-	-
Total body BMC	0.294	-0.559 to 1.148	-	-	<b>7.402</b>	<b>4.106 to 10.699¥</b>	-	-
Total body LM	-0.018	-0.061 to 0.026	-	-	<b>0.301</b>	<b>0.127 to 0.474¥</b>	-	-
Total body %fat	-0.043	-0.098 to 0.011	-	-	-0.208	-0.437 to 0.021	<b>-0.407</b>	<b>-0.622 to -0.193¥</b>
<b>Sociodemographic and clinical characteristics</b>								
Age	<b>-0.051</b>	<b>-0.083 to -0.019‡</b>	<b>-0.051</b>	<b>-0.083 to -0.019‡</b>	<b>-0.165</b>	<b>-0.304 to -0.027‡</b>	<b>-0.175</b>	<b>-0.305 to -0.450*</b>
BMI	-0.038	-0.091 to 0.016	-	-	0.079	-0.148 to 0.307	-	-
Smoking ever	0.453	-0.159 to 1.065	-	-	0.288	-2.318 to 2.893	-	-
Current alcohol use	<b>0.645</b>	<b>0.015 to 1.274*</b>	-	-	<b>3.195</b>	<b>0.564 to 5.827*</b>	-	-
Years since HIV diagnosis	0.022	-0.022 to 0.067	-	-	0.046	-0.142 to 0.234	-	-
Years since ART start	0.035	-0.017 to 0.87	-	-	0.091	-0.128 to 0.311	-	-
Nadir CD4+ count	0.000	-0.002 to 0.001	-	-	0.005	-0.001 to 0.012	-	-
Current CD4+ count	0.000	-0.001 to 0.001	-	-	<b>0.004</b>	<b>0.001 to 0.008*</b>	<b>0.004</b>	<b>0.001 to 0.008*</b>
AIDs diagnosis	-0.688	-1.708 to 0.333	-	-	2.094	-2,225 to 6.412	-	-

Viral suppression status	0.473	-0.192 to 1.139	-	-	-1.298	-4.117 to 1.521	-	-
Menopause status	<b>-0.717</b>	<b>-1.353 to -0.81*</b>	-	-	-0.683	-3.424 to 2.057	-	-
Bone nutritional supplements, ever	-0.200	-1.482 to 1.082	-	-	-2.030	-7.419 to 3.358	-	-

*SPPB, short physical performance battery; FM, fat mass; LM, lean mass; BMC, bone mineral content; BMI, body mass index; %fat, percentage of FM ART, antiretroviral treatment; \*p ≤ 0.05; †p ≤ 0.01; ‡p ≤ 0.001*

233

234 ***Association between clinical characteristics and sarcopenia***

235 Significant associations were found among the HIV-infected univariate model in terms of marital status, where sarcopenia risk reduced with being  
 236 married/cohabitant (OR 0.14, p=0.01). Higher BMI (OR 0.57, p<0.001) and higher current CD4<sup>+</sup> T-cell count (OR 0.99, p<0.5) were also  
 237 significantly associated with reduced sarcopenia risk, and history of AIDS (OR 10.71, p<0.01) and protease inhibitor (PI) exposure (OR 3.53,  
 238 p<0.01) were associated with increased sarcopenia risk. Likewise, in the multivariable model, higher BMI (OR 0.56, p<0.001) and being  
 239 married/cohabitant (OR 0.10, p<0.5) were associated with reduced sarcopenia risk, along with PI exposure (OR 0.19, p<0.01) (Table 5).

240

241

242

243

244

245

246

247 **Table 5.** Unadjusted and Adjusted logistic regression for Sarcopenia Spectrum, HIV-  
 248 infected women (N=104)

249

Independent variables	Sarcopenia Spectrum <sup>a</sup>			
	Unadjusted		Adjusted	
	OR	95% C.I.	OR	95% C.I.
Age	1.000	0.947 to 1.055	0.991	0.919 to 1.069
Married/cohabited marital status	<b>0.140</b>	<b>0.031 to 0.636‡</b>	<b>0.101</b>	<b>0.015 to 0.688*</b>
Education level higher than high school	1.357	0.526 to 3.501	-	-
BMI	<b>0.572</b>	<b>0.447 to 0.732¥</b>	<b>0.566</b>	<b>0.432 to 0.741¥</b>
Smoke, ever	0.714	0.254 to 2.007	-	-
Current alcohol use	0.872	0.307 to 2.479	-	-
Postmenopausal status	0.810	0.293 to 2.34	-	-
Bone nutritional supplements, ever	0.702	0.075 to 6.571	-	-
Years since HIV diagnosis	1.008	0.939 to 1.083	-	-
Years since ART start	0.955	0.877 to 1.040	-	-
Nadir CD4+ count	0.998	0.995 to 1.001	-	-
Current CD4+ count	<b>0.998</b>	<b>0.996 to 1.000*</b>	-	-
Viral suppression status	0.406	0.150 to 1.102	-	-
AIDS diagnosis	<b>10.714</b>	<b>2.013 to 57.022‡</b>	-	-
PI exposure	<b>3.530</b>	<b>1.405 to 8.867‡</b>	<b>0.191</b>	<b>0.050 to 0.728‡</b>
NNRTI exposure	0.582	0.233 to 1.450	-	-

<sup>a</sup>Sarcopenia spectrum: presarcopenia, sarcopenia, severe sarcopenia

BMI, body mass index; ART, antiretroviral treatment; PI, protease inhibitor; NNRTI, nonglucoside reverse transcriptase inhibitor; \* $p \leq 0.05$ ; ‡ $p \leq 0.01$ ; ¥ $p \leq 0.001$

250

## 251 **DISCUSSION**

252 Recognition of aging-related concerns among PLWH, including physical function and  
 253 sarcopenia, is key to distinguishing individuals at greatest risk for downstream  
 254 musculoskeletal complications[10]. Our study is the first to explore the relationship  
 255 between body composition alterations, sarcopenia and physical function among women  
 256 aging with and without HIV in LAC using well-established assessment tools. HIV-infected  
 257 women had significantly lower SPPB scores compared to uninfected women and an  
 258 increased percentage of severe sarcopenia was found in the HIV-infected group.

259 HIV epidemiology in Peru has changed significantly over the past decade. From 2014 to  
 260 2018, the rate of viral suppression among PLWH receiving ART rose from 36% to 65%,

261 due to widespread free antiretroviral access through health clinics around Peru[24].[25].  
262 Consistent with this trend, 78.8% of our HIV-positive sample had an undetectable viral  
263 load. While improved viral control leads to improved survival among PLWH, data  
264 regarding this epidemiological transition among women or men aging with HIV in Peru is  
265 completely lacking, and is quite limited from other countries in the LAC region [26].[27].

266 Changes in body composition, such as fat redistribution, have been shown to impact  
267 physical function and risk for mortality[1]. Since 2013, the International Society for  
268 Clinical Densitometry has included ART use in PLWH as one of the indications for using  
269 DXA-based body measurements of body composition, in particular for patients receiving  
270 agents associated with risk of lipoatrophy [28,29]. Among these changes, peripheral  
271 (face and limbs) fat atrophy is commonly reported[30,31]. In our study, women with HIV  
272 had lower FM in the limbs and trunk compared to uninfected women, a finding that was  
273 statistically significant. Prevalence of fat redistribution varies widely across reports (7-  
274 65%) in low- and middle-income countries (LMICs)[32], and in LAC, only one study from  
275 Brazil has assessed body composition changes in PLWH with objective measurements  
276 such as DXA scan. Among 262 PLWH (43% women) the authors found a 40.8% overall  
277 prevalence of lipodystrophy based upon DXA-derived fat mass ratio, underscoring the  
278 importance of early screening and intervention in this population to prevent  
279 complications[33]. Interestingly, in the Brazilian sample, prevalence of lipodystrophy  
280 measured by DXA among women was only 15.8%, compared to 48.8% among men  
281 ( $p<0.05$ ), however the authors attributed this finding to their use of a cutoff for  
282 lipodystrophy that was previously standardized in men, but not women, as the  
283 prevalence of lipodystrophy among women measured by clinical exam was 56.5% in  
284 women, versus 47.7% in men.

285 In terms of impact of these anthropometric changes on physical performance of PLWH,  
286 studies conducted in upper-income countries have reported that HIV-infected individuals  
287 appear to have worse physical function compared to those without HIV[34–36]. Among

288 participants in our study, women with HIV had a modestly but significantly lower SPPB  
289 score compared to the control group. Compared to another study of 176 PLWH (19%  
290 women) in the United States (US) with mean age of 54.6 years, both HIV-infected and  
291 infected women of our sample had lower SPPB scores[12]. Additionally, 16.4% of HIV-  
292 infected and 4% of uninfected women in our study had a SPPB score  $\leq 8$  points, which  
293 has been shown to be predictive for subsequent disability and mortality[16,37]. A similar  
294 study among 65 middle-aged and older (45-55 years) women with HIV in the US with  
295 well-controlled disease (mean current CD4<sup>+</sup> T-cell 675 cells/mm<sup>3</sup>, 89% viral load <75  
296 copies/mL) found that 20% of women met criteria for low physical function based upon  
297 the SPPB[38]. Even though in our study population, HIV-related biomarkers were  
298 relatively stable (mean CD4<sup>+</sup> 593.3 cell/mm<sup>3</sup>; 78.4% viral suppression), a considerable  
299 difference was detected in terms of proportion of women with SPPB score  $\leq 8$  in the HIV-  
300 infected versus uninfected groups. Accordingly, one of the largest studies to apply the  
301 SPPB in PLWH found that having well-controlled CD4<sup>+</sup> T-cell counts and viral load  
302 moderated, but did not eliminate, the odds of reduced physical performance compared  
303 the general population[10].

304 In our study, older age was negatively associated with SPPB score in both HIV-infected  
305 and uninfected women. These findings are consistent with the scarce literature  
306 conducted mostly in upper-income countries, and to a lesser extent,  
307 Africa[12,38,39]. Furthermore, trunk FM was negatively associated with SPPB in the  
308 multivariable analyses for both HIV-infected and uninfected women. These results are  
309 similar to those reported in previous studies in different aging populations[40–43],  
310 however, none of them included HIV-infected individuals.

311 In terms of physical strength, upper limb LM was positively associated with grip strength  
312 in regression models for both HIV-infected and uninfected individuals, consistent with  
313 previous evidence describing muscle mass as an important predictor of physical  
314 function[43]. In our study, although total body LM was slightly higher in uninfected

315 women, differences were not significant. Moreover, among the HIV-infected multivariate  
316 model, total body fat percentage was negatively correlated with grip strength, which is  
317 also in line with the negative relationship observed in our study between trunk FM and  
318 SPPB scores. The mechanisms and natural history of altered lean mass among aging  
319 PLWH receiving ART remain poorly understood. Grant et al. described a “return to health  
320 effect” where PLWH gained more LM during the first 96 weeks of ART than HIV-  
321 uninfected individuals as their immune function and overall health status improves with  
322 treatment. However, after that period, patients with HIV had a decrease in LM despite  
323 virologic suppression[1]. Other studies have demonstrated a correlation between  
324 elevated proinflammatory cytokine levels (e.g. interleukin-6 and C-reactive protein) with  
325 low lean mass[44].

326 Lean or muscle mass is another body compartment frequently affected by HIV[1]. To  
327 date, studies on sarcopenia among PLWH are limited and have applied different  
328 operational definitions[8]. To our knowledge, ours is the first study that reports  
329 sarcopenia among Peruvian women with HIV using the EWGSOP recommendations.  
330 The rationale behind this multicomponent definition, which takes into account muscle  
331 mass, function and strength, is that characterizing sarcopenia simply in terms of muscle  
332 mass significantly limits the clinical utility of the definition[45]. In our study, the majority  
333 of women that presented with this syndrome were classified as “sarcopenia” stage.  
334 Likewise, a recent metanalysis across 13 studies of PLWH (range: 35-60 years of age)  
335 from different geographic regions, including two studies from Brazil, found a pooled  
336 sarcopenia prevalence of 13.2% (CI=5.2-22.9%) using two operational definitions. These  
337 included (1) the presence of low LM (four studies) measured by DXA or bioimpedance  
338 analysis, or (2) the EWGSOP definition (nine studies)[46]. Our multivariable regression  
339 model found that BMI, protease inhibitor (PI) exposure and being married/cohabitant  
340 were negatively associated with a sarcopenia spectrum diagnosis. Some of these  
341 associations are consistent with previous reports, where higher BMI was associated with

342 a lower odds of sarcopenia[46]. However, although PI exposure was positively  
343 associated with sarcopenia in the unadjusted analysis, in the multivariable model it was  
344 a protective factor, which contradicts previous data demonstrating increased risk of body  
345 composition and metabolic alterations[47,48]. Moreover, in our sample of patients, the  
346 proportion of “severe sarcopenia” was higher in the HIV-infected women compared to  
347 uninfected group (3.8% vs 0.9%), however this difference did not achieve statistical  
348 significance perhaps due to the limited sample size. This finding may suggest worse  
349 prognosis for HIV-positive individuals and warrants further evaluation in larger-scale,  
350 longitudinal studies.

351 This study has some important limitations. First, as this was a single-center study our  
352 findings might not be generalizable to all women with HIV in Peru, nor to those outside  
353 Peru due to differences in cultural and environmental factors. However, this study was  
354 conducted in one of the largest public HIV clinics in Peru’s capital city. Second, the cross-  
355 sectional nature of our study means that associations between physical strength,  
356 performance measures, and sarcopenia spectrum outcomes cannot be inferred to  
357 suggest causality, furthermore, we didn’t carry out a power calculation, limiting the  
358 statistical power of this study. However, our goal was to explore possible relationships  
359 between body composition and physical function to further promote future studies in this  
360 topic among Latin American populations. Finally, the EWGSOP published updated  
361 guidelines in 2019[49] that propose a new algorithm for screening and diagnosing  
362 sarcopenia, which incorporates the SARC-F screening tool and a slightly modified  
363 sequence of the sarcopenia components used in the original guidelines (LM, muscle  
364 strength and physical performance). As this new algorithm utilizes European region-  
365 specific cutoff thresholds which have not yet been adapted to Latin American populations  
366 (whereas in certain regions such as Asia, corresponding guidelines have already been  
367 published with thresholds specifically to Asian populations[50]), we opted to apply the  
368 well-established 2010 EWGSOP guidelines which have been utilized previously in LAC

369 populations[51]. Future studies are needed to test and develop appropriate threshold for  
370 the new EWGSOP algorithm among individuals from LAC.

371 In summary, as HIV increasingly shifts to a chronic condition, and the proportion of  
372 patients aging with HIV globally continues to grow, research characterizing the effect of  
373 aging-related comorbidities among this population using well-validated tools is critically  
374 needed[52]. Much remains unknown regarding the extent to which alterations in body  
375 composition impact physical function and sarcopenia among women with HIV. We found  
376 that HIV-infected women in our study had significantly lower SPPB scores compared to  
377 uninfected women, and that trunk FM and upper limb LM were independent predictors  
378 for physical function. Additionally, a higher prevalence of severe sarcopenia was  
379 observed among HIV-infected women in our study. These findings underscore the  
380 necessity for larger prospective studies among PLWH, particularly in LAC, to help identify  
381 individuals at greatest risk for declines in physical function and sarcopenia. Our data  
382 suggest that targeting lower trunk/abdominal fat mass and increasing limb lean mass  
383 could potentially have a positive impact on physical function outcomes. However,  
384 intervention studies are needed to inform clinical practice guidelines with regards to  
385 optimizing musculoskeletal health among women with HIV.

386

387 **Acknowledgments:** We thank Debbie Miyasato, Eduardo Matos, Ana Maria Guerrero,  
388 Maricruz Huaman, Karim Sanchez, Rocio Galvez and Miriam Santos from the HIV clinic  
389 and Radiology Department at Hospital Nacional Arzobispo Loayza for their invaluable  
390 help during data collection. Additionally, we greatly thank Cesar Cárcamo for his  
391 important input regarding data analysis.

392

393

394

395 **REFERENCES**

- 396 1. Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, et al. Long-term body  
397 composition changes in antiretroviral-treated HIV-infected individuals. *AIDS*. 2016;30:  
398 2805–2813. doi:10.1097/QAD.0000000000001248
- 399 2. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-  
400 related comorbidities among HIV-infected persons compared with the general  
401 population. *Clin Infect Dis*. 2011;53: 1120–1126. doi:10.1093/cid/cir627
- 402 3. Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and  
403 inflammation in patients with HIV infection. *Clin Exp Immunol*. 2017;187: 44–52.  
404 doi:10.1111/cei.12814
- 405 4. Cabrera DM, Diaz MM, Grimshaw A, Salvatierra J, Garcia PJ, Hsieh E. Aging with HIV in  
406 Latin America and the Caribbean: a Systematic Review. *Curr HIV/AIDS Rep*. 2021;18: 1–  
407 47. doi:10.1007/s11904-020-00538-7
- 408 5. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al.  
409 Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral  
410 therapy: *AIDS*. 2000;14: F63–F67. doi:10.1097/00002030-200003100-00005
- 411 6. Sacilotto LB, Pereira PCM, Manechini JPV, Papini SJ. Body Composition and Metabolic  
412 Syndrome Components on Lipodystrophy Different Subtypes Associated with HIV. *J Nutr*  
413 *Metab*. 2017;2017: 8260867. doi:10.1155/2017/8260867
- 414 7. Sharma A, Tian F, Yin MT, Keller MJ, Cohen M, Tien PC. Association of Regional Body  
415 Composition with Bone Mineral Density in HIV-infected and Uninfected Women:  
416 Women’s Interagency HIV Study. *J Acquir Immune Defic Syndr*. 2012;61: 469–476.  
417 doi:10.1097/QAI.0b013e31826cba6c
- 418 8. Abdul Aziz SA, Mcstea M, Ahmad Bashah NS, Chong ML, Ponnampalavanar S, Syed Omar  
419 SF, et al. Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving  
420 treatment. *AIDS*. 2018;32: 1025–1034. doi:10.1097/QAD.0000000000001798
- 421 9. Brañas F, Jiménez Z, Sánchez-Conde M, Dronda F, López-Bernaldo De Quirós JC, Pérez-  
422 Elías MJ, et al. Frailty and physical function in older HIV-infected adults. *Age and Ageing*.  
423 2017;46: 522–526. doi:10.1093/ageing/afx013
- 424 10. Greene M, Covinsky K, Astemborski J, Piggott DA, Brown T, Leng S, et al. The relationship  
425 of physical performance with HIV disease and mortality. *AIDS*. 2014;28: 2711–2719.  
426 doi:10.1097/QAD.0000000000000507
- 427 11. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short  
428 physical performance battery assessing lower extremity function: association with self-  
429 reported disability and prediction of mortality and nursing home admission. *J Gerontol*.  
430 1994;49: M85–94. doi:10.1093/geronj/49.2.m85
- 431 12. Crane HM, Miller ME, Pierce J, Willig AL, Case ML, Wilkin AM, et al. Physical Functioning  
432 Among Patients Aging With Human Immunodeficiency Virus (HIV) Versus HIV Uninfected:  
433 Feasibility of Using the Short Physical Performance Battery in Clinical Care of People

- 434 Living With HIV Aged 50 or Older. *Open Forum Infect Dis.* 2019;6.  
435 doi:10.1093/ofid/ofz038
- 436 13. Brañas F, Sánchez-Conde M, Carli F, Menozzi M, Raimondi A, Milic J, et al. Sex Differences  
437 in People Aging With HIV: *JAIDS Journal of Acquired Immune Deficiency Syndromes.*  
438 2020;83: 284–291. doi:10.1097/QAI.0000000000002259
- 439 14. Hou Y, Xie Z, Zhao X, Yuan Y, Dou P, Wang Z. Appendicular skeletal muscle mass: A more  
440 sensitive biomarker of disease severity than BMI in adults with mitochondrial diseases.  
441 *PLoS One.* 2019;14. doi:10.1371/journal.pone.0219628
- 442 15. Short Physical Performance Battery (SPPB). In: National Institute on Aging [Internet].  
443 [cited 6 Jun 2020]. Available: [https://www.nia.nih.gov/research/labs/leps/short-physical-](https://www.nia.nih.gov/research/labs/leps/short-physical-performance-battery-sppb)  
444 [performance-battery-sppb](https://www.nia.nih.gov/research/labs/leps/short-physical-performance-battery-sppb)
- 445 16. Erlandson KM, Allshouse AA, Jankowski CM, Duong S, MaWhinney S, Kohrt WM, et al. A  
446 Comparison of Functional Status Instruments in HIV-Infected Adults on Effective  
447 Antiretroviral Therapy. *HIV Clin Trials.* 2012;13: 324–334. doi:10.1310/hct1306-324
- 448 17. Alahmari KA, Silvian SP, Reddy RS, Kakaraparthi VN, Ahmad I, Alam MM. Hand grip  
449 strength determination for healthy males in Saudi Arabia: A study of the relationship  
450 with age, body mass index, hand length and forearm circumference using a hand-held  
451 dynamometer. *J Int Med Res.* 2017;45: 540–548. doi:10.1177/0300060516688976
- 452 18. Leong DP, Teo KK, Rangarajan S, Kutty VR, Lanan F, Hui C, et al. Reference ranges of  
453 handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural  
454 epidemiologic (PURE) study. *J Cachexia Sarcopenia Muscle.* 2016;7: 535–546.  
455 doi:10.1002/jcsm.12112
- 456 19. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia:  
457 European consensus on definition and diagnosis. *Age Ageing.* 2010;39: 412–423.  
458 doi:10.1093/ageing/afq034
- 459 20. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al.  
460 Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol.* 1998;147:  
461 755–763. doi:10.1093/oxfordjournals.aje.a009520
- 462 21. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al. Age-associated  
463 changes in skeletal muscles and their effect on mobility: an operational diagnosis of  
464 sarcopenia. *J Appl Physiol.* 2003;95: 1851–1860. doi:10.1152/jappphysiol.00246.2003
- 465 22. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower  
466 extremity function and subsequent disability: consistency across studies, predictive  
467 models, and value of gait speed alone compared with the short physical performance  
468 battery. *J Gerontol A Biol Sci Med Sci.* 2000;55: M221-231.  
469 doi:10.1093/gerona/55.4.m221
- 470 23. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of  
471 functional form for continuous predictors in multivariable model building. *Stat Med.*  
472 2007;26: 5512–5528. doi:10.1002/sim.3148

- 473 24. Cáceres C. Estudio sobre el Continuo de Atención de las Personas con VIH. Lima, Perú:  
474 Centro de Investigación Interdisciplinaria en sexualidad, SIDA y Sociedad; 2019 p. 71.  
475 Report No.: 8.
- 476 25. Garcia-Fernandez L, Novoa R, Huaman B, Benites C. Continuo de la atención de personas  
477 que viven con VIH y brechas para el logro de las metas 90-90-90 en Perú. Revista Peruana  
478 de Medicina Experimental y Salud Publica. 2018;35: 491–496.  
479 doi:10.17843/rpmesp.2018.353.3853
- 480 26. Cardoso SW, Torres TS, Santini-Oliveira M, Marins LMS, Veloso VG, Grinsztejn B. Aging  
481 with HIV: a practical review. The Brazilian Journal of Infectious Diseases. 2013;17: 464–  
482 479. doi:10.1016/j.bjid.2012.11.007
- 483 27. Crabtree-Ramirez B, Del Rio C, Grinsztejn B, Sierra-Madero J. HIV and noncommunicable  
484 diseases (NCDs) in Latin America: A call for an integrated and comprehensive response.  
485 Journal of Acquired Immune Deficiency Syndromes. 2014;67: S96–S98.  
486 doi:10.1097/QAI.0000000000000261
- 487 28. Shepherd JA, Baim S, Bilezikian JP, Schousboe JT. Executive summary of the 2013  
488 International Society for Clinical Densitometry Position Development Conference on  
489 Body Composition. J Clin Densitom. 2013;16: 489–495. doi:10.1016/j.jocd.2013.08.005
- 490 29. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive  
491 Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment,  
492 DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic  
493 and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom.  
494 2019;22: 453–471. doi:10.1016/j.jocd.2019.07.001
- 495 30. Chițu-Tișu CE, Barbu EC, Lazăr M, Bojincă M, Tudor A-M, Hristea A, et al. Body  
496 composition in HIV-infected patients receiving highly active antiretroviral therapy. Acta  
497 Clinica Belgica. 2017;72: 55–62. doi:10.1080/17843286.2016.1240426
- 498 31. Nuvoli S, Caruana G, Babudieri S, Solinas P, Pellicanò G, Piras B, et al. Body fat changes in  
499 HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study.  
500 European Review for Medical and Pharmacological Sciences. 2018;22: 1852–1859.  
501 doi:10.26355/eurrev\_201803\_14606
- 502 32. Ali MK, Magee MJ, Dave JA, Ofotokun I, Tungsiripat M, Jones TK, et al. HIV and metabolic,  
503 body, and bone disorders: what we know from low- and middle-income countries. J  
504 Acquir Immune Defic Syndr. 2014;67 Suppl 1: S27-39.  
505 doi:10.1097/QAI.0000000000000256
- 506 33. Beraldo RA, Santos AP dos, Guimarães MP, Vassimon HS, Paula FJA de, Machado DRL, et  
507 al. Redistribuição de gordura corporal e alterações no metabolismo de lipídeos e glicose  
508 em pessoas vivendo com HIV/AIDS. Revista Brasileira de Epidemiologia. 2017;20: 526–  
509 536. doi:10.1590/1980-5497201700030014
- 510 34. Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, et al. Factors  
511 associated with preclinical disability and frailty among HIV-infected and HIV-uninfected  
512 women in the era of cART. J Womens Health (Larchmt). 2009;18: 1965–1974.  
513 doi:10.1089/jwh.2008.1090

- 514 35. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1  
515 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty. *J*  
516 *Gerontol A Biol Sci Med Sci*. 2007;62: 1279–1286. doi:10.1093/gerona/62.11.1279
- 517 36. Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, et al. Frailty, HIV  
518 infection, and mortality in an aging cohort of injection drug users. *PLoS ONE*. 2013;8:  
519 e54910. doi:10.1371/journal.pone.0054910
- 520 37. Pavasini R, Guralnik J, Brown JC, di Bari M, Cesari M, Landi F, et al. Short Physical  
521 Performance Battery and all-cause mortality: systematic review and meta-analysis. *BMC*  
522 *Med*. 2016;14. doi:10.1186/s12916-016-0763-7
- 523 38. Baranoski AS, Harris A, Michaels D, Miciek R, Storer T, Sebastiani P, et al. Relationship  
524 Between Poor Physical Function, Inflammatory Markers, and Comorbidities in HIV-  
525 Infected Women on Antiretroviral Therapy. *J Womens Health (Larchmt)*. 2014;23: 69–76.  
526 doi:10.1089/jwh.2013.4367
- 527 39. Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, et al.  
528 Implementing routine physical function screening among elderly HIV-positive patients in  
529 Uganda. *AIDS Care*. 2019; 1–4. doi:10.1080/09540121.2019.1703888
- 530 40. Kim JH, Chon J, Soh Y, Han YR, Won CW, Lee SA. Trunk fat mass correlates with balance  
531 and physical performance in a community-dwelling elderly population: Results from the  
532 Korean Frailty and aging cohort study. *Medicine*. 2020;99: e19245.  
533 doi:10.1097/MD.00000000000019245
- 534 41. Hicks GE, Simonsick EM, Harris TB, Newman AB, Weiner DK, Nevitt MA, et al. Trunk  
535 muscle composition as a predictor of reduced functional capacity in the health, aging and  
536 body composition study: the moderating role of back pain. *J Gerontol A Biol Sci Med Sci*.  
537 2005;60: 1420–1424. doi:10.1093/gerona/60.11.1420
- 538 42. Woo J, Leung J, Kwok T. BMI, body composition, and physical functioning in older adults.  
539 *Obesity (Silver Spring)*. 2007;15: 1886–1894. doi:10.1038/oby.2007.223
- 540 43. Valentine RJ, Misisic MM, Rosengren KS, Woods JA, Evans EM. Sex impacts the relation  
541 between body composition and physical function in older adults. *Menopause*. 2009;16:  
542 518–523. doi:10.1097/gme.0b013e31818c931f
- 543 44. PrayGod G, Blevins M, Woodd S, Rehman AM, Jeremiah K, Friis H, et al. A longitudinal  
544 study of systemic inflammation and recovery of lean body mass among malnourished  
545 HIV-infected adults starting antiretroviral therapy in Tanzania and Zambia. *Eur J Clin Nutr*.  
546 2016;70: 499–504. doi:10.1038/ejcn.2015.221
- 547 45. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss  
548 of skeletal muscle strength, mass, and quality in older adults: the health, aging and body  
549 composition study. *J Gerontol A Biol Sci Med Sci*. 2006;61: 1059–1064.  
550 doi:10.1093/gerona/61.10.1059
- 551 46. Oliveira VHF, Borsari AL, Webel AR, Erlandson KM, Deminice R. Sarcopenia in people  
552 living with the Human Immunodeficiency Virus: a systematic review and meta-analysis.  
553 *Eur J Clin Nutr*. 2020;74: 1009–1021. doi:10.1038/s41430-020-0637-0

- 554 47. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of  
555 lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included  
556 with protease inhibitors in the treatment of HIV-1 infection. *AIDS*. 2001;15: 847–855.  
557 doi:10.1097/00002030-200105040-00005
- 558 48. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose  
559 tolerance, beta cell function and lipid metabolism in HIV patients under treatment with  
560 protease inhibitors. *AIDS*. 1999;13: F63-70. doi:10.1097/00002030-199907090-00001
- 561 49. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia:  
562 revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48: 16–31.  
563 doi:10.1093/ageing/afy169
- 564 50. Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, et al. Asian Working  
565 Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J*  
566 *Am Med Dir Assoc*. 2020;21: 300-307.e2. doi:10.1016/j.jamda.2019.12.012
- 567 51. da Silva Alexandre T, de Oliveira Duarte YA, Ferreira Santos JL, Wong R, Lebrão ML.  
568 Sarcopenia according to the european working group on sarcopenia in older people  
569 (EWGSOP) versus Dynapenia as a risk factor for disability in the elderly. *J Nutr Health*  
570 *Aging*. 2014;18: 547–553. doi:10.1007/s12603-014-0465-9
- 571 52. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, et al. HIV and Aging:  
572 State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of  
573 AIDS Research by the HIV and Aging Working Group. *JAIDS Journal of Acquired Immune*  
574 *Deficiency Syndromes*. 2012;60: S1–S18. doi:10.1097/QAI.0b013e31825a3668

575

576

## 577 **DECLARATIONS**

578 **Funding:** Dr. Diego M. Cabrera serves as a Fogarty Global Health Trainee and is  
579 supported by the Fogarty International Center (FIC) at the National Institutes of Health  
580 (NIH) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases  
581 (NIAMS) under grant number D43TW010540. Dr. Evelyn Hsieh is supported by  
582 NIH/Fogarty International Center K01TW009995

583 **Conflict of interest/Competing interests:** The authors have no relevant financial or  
584 non-financial interests to disclose.

585 **Ethics approval:** This study was reviewed and approved by the institutional review  
586 boards of Yale School of Medicine, Universidad Peruana Cayetano Heredia and Hospital

587 Nacional Arzobispo Loayza. The procedures used in this study adhere to the tenets of  
588 the Declaration of Helsinki.

589 **Consent to participate:** All willing participants provided written informed consent after  
590 a comprehensive explanation of the study procedures

591 **Consent for publication:** All participants enrolled provided consent for publication of  
592 de-identified data in journal article

593 **Availability of data and material:** All data and material are available for data  
594 transparency purposes and are available from corresponding author on reasonable  
595 request

596 **Code availability:** All statistical code is available for data transparency purposes

597 **Authors contributions:** Diego M. Cabrera, Evelyn Hsieh and Patricia J. Garcia  
598 contribute to study conception, design, material preparation, data collection and analysis,  
599 manuscript preparation, review and editing. Mijahil P. Cornejo and Yvett Pinedo were  
600 involved in implementation, data collection and manuscript review. All authors read and  
601 approved the final manuscript.